摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-[(3S)-6-chloro-1,2,3,4-tetrahydroquinolin-3-yl]-N,N-dimethylmethanamine | 333954-53-3

中文名称
——
中文别名
——
英文名称
1-[(3S)-6-chloro-1,2,3,4-tetrahydroquinolin-3-yl]-N,N-dimethylmethanamine
英文别名
1-[(3S)-6-chloro-1,2,3,4-tetrahydroquinolin-3-yl]-N.N-dimethylmethanamine;6-chloro-3-(S)-[(N,N-dimethylamino)methyl]-1,2,3,4-tetrahydroquinoline
1-[(3S)-6-chloro-1,2,3,4-tetrahydroquinolin-3-yl]-N,N-dimethylmethanamine化学式
CAS
333954-53-3
化学式
C12H17ClN2
mdl
——
分子量
224.733
InChiKey
JUXRCKHOUDDWQI-VIFPVBQESA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    115-116 °C
  • 沸点:
    334.2±35.0 °C(Predicted)
  • 密度:
    1.093±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.9
  • 重原子数:
    15
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    15.3
  • 氢给体数:
    1
  • 氢受体数:
    2

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • AMINE DERIVATIVES
    申请人:Tadeka Chemical Industries, Ltd.
    公开号:EP1227090A1
    公开(公告)日:2002-07-31
    A compound of the formula:    wherein X and X' are the same or different, and each represents a hydrogen atom, a fluorine atom, a chlorine atom or an amino optionally having substituents, and at least one of X and X' represents a fluorine atom, a chlorine atom or an amino optionally having substituents; R1 and R2 represent a hydrogen atom or C1-6 alkyl optionally having substituents, or R1 and R2, together with the adjacent nitrogen atom, form a nitrogen-containing heterocyclic ring optionally having substituents; Y and Q are the same or different, and each represents a bond or a spacer having a main chain of 1 to 6 atoms; ... represents a single bond or a double bond; T1 and T2 are the same or different, and each represents C(R9) (R9 represents a hydrogen atom, a hydroxy or C1-6 alkyl) or N, when each of the adjacent ... is a single bond, and C when the adjacent ... is a double bond; and Ar represents an aromatic group optionally having substituents, a C3-9 cycloalkyl group optionally having substituents, a 3 to 9-membered saturated heterocyclic group optionally having substituents, a hydrogen atom or a halogen atom; provided that 6-chloro-3-(R,S)-(N,N-dimethylamino)methyl-1-[3-(indol-3-yl)-2-[(R)-(4-phenylpiperazin-1-yl)carbonylamino]propanoyl]-1,2,3,4-tetrahydroquinoline; 6-chloro-3-(R,S)-(N,N-dimethylamino)methyl-1-[3-(indol-3-yl)-2-[(R)-4-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)piperidinocarbonylamino]propanoyl]-1,2,3,4-tetrahydroquinoline and 1-benzoyl-N-[(R)-2-[6-chloro-3-[(N,N-dimethylamino)methyl]-1,2,3,4-tetrahydroquinolin-1-yl]-1-[3-(indol-3-yl)propanoyl]-4-piperidinecarboxamide are excluded; a salt thereof or a prodrug thereof has an excellent somatostatin receptor binding inhibition action and is useful for preventing and/or treating diseases associated with somatostatin.
    式中的化合物 X和X'相同或不同,各自代表氢原子、氟原子、氯原子或可选具有取代基的氨基,且X和X'中至少有一个代表氟原子、氯原子或可选具有取代基的氨基; R1 和 R2 代表氢原子或任选具有取代基的 C1-6 烷基,或 R1 和 R2 与相邻的氮原子一起形成任选具有取代基的含氮杂环; Y 和 Q 相同或不同,各自代表主链为 1 至 6 个原子的键或间隔物; 代表单键或双键; T1 和 T2 相同或不同,当相邻......中的每一个为单键时,各自代表 C(R9)(R9 代表氢原子、羟基或 C1-6 烷基)或 N,当相邻......中的每一个为双键时,各自代表 C;以及 Ar 代表任选具有取代基的芳香基、任选具有取代基的 C3-9 环烷基、任选具有取代基的 3-9 元饱和杂环基、氢原子或卤素原子;条件是 6-氯-3-(R,S)-(N,N-二甲基氨基)甲基-1-[3-(吲哚-3-基)-2-[(R)-(4-苯基哌嗪-1-基)羰基氨基]丙酰基]-1,2,3,4-四氢喹啉;6-氯-3-(R,S)-(N,N-二甲基氨基)甲基-1-[3-(吲哚-3-基)-2-[(R)-4-(2-氧代-2,3-二氢-1H-苯并咪唑-1-基)哌啶甲酰氨基]丙酰基]-1,2,3,4-四氢喹啉不包括 1-苯甲酰基-N-[(R)-2-[6-氯-3-[(N,N-二甲基氨基)甲基]-1,2,3,4-四氢喹啉-1-基]-1-[3-(吲哚-3-基)丙酰基]-4-哌啶甲酰胺;其盐或其原药具有优异的抑制体生长抑素受体结合的作用,可用于预防和/或治疗与体生长抑素相关的疾病。
  • AMINE DERIVATIVE
    申请人:Takeda Chemical Industries, Ltd.
    公开号:EP1437351A1
    公开(公告)日:2004-07-14
    The present invention provide a compound of the formula: wherein X and X' are the same or different and each represents a hydrogen atom, etc.; R1 and R2 are the same or different and each represents a hydrogen atom, etc.; R3 represents a hydrocarbon group optionally having substituents, etc.; R4 represents a hydrogen atom, etc.; Y and Ya are the same or different and each represents a bond or a spacer having a main chain of 1 to 8 atoms; Z and Za are the same or different and each represents a hydrogen atom, etc.; or a salt thereof or a prodrug thereof, having a somatostatin receptor binding inhibitory activity and is useful for preventing and/or treating diseases associated with somatostatin.
    本发明提供一种式的化合物: 其中X和X'相同或不同,各自代表氢原子等;R1和R2相同或不同,各自代表氢原子等;R3代表任选具有取代基的烃基等;R4代表氢原子等。Y和Ya相同或不同,各自代表键或具有1至8个原子的主链的间隔物;Z和Za相同或不同,各自代表氢原子等;或其盐或其原药,具有抑制体生长抑素受体结合的活性,可用于预防和/或治疗与体生长抑素相关的疾病。
  • EP1437351
    申请人:——
    公开号:——
    公开(公告)日:——
  • Process for the Preparation of an Amorphous, Peptide-like Diabetes Drug: Approach to a Chromatography-Free Process
    作者:Yasuhiro Sawai、Taihei Yamane、Motoki Ikeuchi、Shinji Kawaguchi、Masatoshi Yamada、Mitsuhisa Yamano
    DOI:10.1021/op100084r
    日期:2010.9.17
    A manufacturing process suitable for large-scale production of the peptide-like amorphous compound N-((R)-1-(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydroquinolin-1(2H)-yl}-3-(H-indo1-3-yl)-1-oxopropan-2-yl)-1-[(1-methyl-1H-indol-2-yl)carbon-yl]piperidine-4-carboxamide (1) as a drug for treating diabetes has been developed. The first kilogram quantities of 1 were prepared via a single-chromatography process that employed recyclable cation-exchange resin chromatography for an amorphous intermediate (2R)-2-amino-1-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydroquinolin-1(2H)-yl]-3-(1H-indol-3-y1)-propan-1-one (syn-3a). We have also developed a chromatography-free process that involves a combination purification of extraction of syn-3a with crystallization of syn-3a center dot 0.25H(3)PO(4)center dot 0.5H(2)O. The latter process afforded amorphous compound 1 with >98% purity by HPLC area analysis, the same quality as that provided by the former process.
  • EP1227090
    申请人:——
    公开号:——
    公开(公告)日:——
查看更多